Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 4/20 | 0.51 |
| ▸ | DGKZ | Q13574 | 4/20 | 0.51 |
| ▸ | HCRTR2 | O43614 | 14/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 13/20 | 0.39 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30554480 | 1.00 | DGKA (0.51) | DGKADGKZHCRTR2HCRTR1KDM4D | |
| SCHEMBL29922451 | 0.90 | DGKA (0.48) | DGKADGKZHCRTR2HCRTR1KDM4D | |
| SCHEMBL21831500 | 0.87 | DGKA (0.55) | DGKADGKZHCRTR2HCRTR1MAPK14 | |
| SCHEMBL25327774 | 0.87 | DGKA (0.55) | DGKADGKZHCRTR2HCRTR1MAPK14 | |
| SCHEMBL30554398 | 0.86 | DGKA (0.39) | DGKADGKZHCRTR2KDM4DMAPK14 | |
| SCHEMBL21911507 | 0.86 | DGKA (0.39) | DGKADGKZHCRTR2KDM4DMAPK14 | |
| SCHEMBL21910422 | 0.84 | DGKA (0.37) | DGKADGKZHCRTR2HCRTR1KDM4D | |
| SCHEMBL30554462 | 0.84 | DGKA (0.37) | DGKADGKZHCRTR2HCRTR1KDM4D | |
| SCHEMBL29922480 | 0.83 | MAPK14 (0.44) | DGKADGKZKDM4DMAPK14 | |
| SCHEMBL29922490 | 0.83 | MAPK14 (0.44) | DGKADGKZKDM4DMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112654621-B | Substituted naphthyridinone compounds useful as T cell activators | 百时美施贵宝公司 | 2024-05-14 | — | — | CN | disclosed |
| EP-3814348-B9 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-11-01 | — | — | EP | disclosed |
| EP-3814348-B1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11713316-B2 | Substituted naphthyridinone compounds useful as T cell activators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-01 | — | — | US | disclosed |
| US-20220324859-A1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220324859-A1 | SUBSTITUTED NAPHTHYRIDINONE COMPOUNDS USEFUL AS T CELL ACTIVATORS | DGKZ, DGKA, DGKG | DGKA 2/4885DGKZ 1/4885HCRTR2 4502/4885 |
| US-11713316-B2 | Substituted naphthyridinone compounds useful as T cell activators | DGKZ, DGKA, DGKG | DGKA 2/4885DGKZ 1/4885HCRTR2 4502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.